A Phase 1, Open-Label, Multicenter Study of Treatment with ACE1831, Comprised of Allogeneic Gamma Delta T Cells Conjugated to an Anti-CD-20 Antibody, in Patients (Pts) with B-Cell Relapsed/Refractory Non-Hodgkin&#39;s Lymphoma (R/R NHL)

Gazyva (obinutuzumab) - Roche, Biogen

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

ACE1831 - Acepodia

https://www.sciencedirect.com/science/article/pii/S0006497124100766

Don A. Stevens MD 1; Jason T Romancik MD 2; Rushang D. Patel MD PhD 3; Ranjit Nair MD 4; Janet Pan 5; Stephanie Chien 5; Ifeoluwapo Olorunyomi 5; Sai-Wen Tang 5; Heather Kelley 5; Jerry Liu MD 5; Michael Kurman MD 6

Dec 7, 2024